Test Price
2,800 AED✅ Home Collection Available
MYO6 Gene Deafness Autosomal Dominant Type 22 (DFNA22) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- • Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- • Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM).
- • Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation with a DHA-licensed genetic counsellor.
- • Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 — instant pre‑approval.
Test Overview & Methodology
The MYO6 gene NGS test identifies pathogenic variants in the MYO6 gene linked to autosomal dominant non‑syndromic hearing loss (DFNA22), enabling precise genetic diagnosis and informed clinical management. This test utilizes Next Generation Sequencing technology with a turnaround time of 3‑4 weeks.
| Feature | Our Test (MYO6 NGS) | Closest Alternative (Standard Single‑Gene Sequencing) |
|---|---|---|
| Diagnostic Precision | >99.9% analytical sensitivity, full gene coverage | ~95% for targeted regions only |
| Methodology | High‑depth Next Generation Sequencing (NGS) | Sanger sequencing (limited to known hotspots) |
| Turnaround | 3–4 Weeks | 4–6 Weeks |
| Detection Scope | All coding exons, splice sites, and deep intronic regions | Selected exons only |
| Clinical Utility | Confirms DFNA22 diagnosis, guides cochlear implant candidacy | May miss atypical variants |
Physician Insight & Safety Protocols
“This MYO6 gene test offers families a definitive molecular answer for autosomal dominant hearing loss, but a positive variant must be correlated with an audiogram and family history. I urge every patient to view their result as one piece of the clinical puzzle and to always involve an ENT specialist and clinical geneticist before making irreversible decisions.” — Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
⚠️ Advisory: Medication and Treatment Precautions
Do not discontinue prescribed medication or modify hearing aid/cochlear implant settings without consulting your doctor. Genetic results do not replace current audiological treatment plans.
Patient Safety & Exclusion Criteria
- Exclusion Criteria: Inability to provide a blood sample or extracted DNA; patients who cannot give informed consent for genetic testing under Federal Decree-Law No. 4 of 2016 on Medical Liability (minors require legal guardian consent).
- ER Red Flags: Sudden severe hearing loss, acute vertigo, or suicidal ideation after receiving genetic information—seek immediate medical attention.
- Privacy: All genetic data is protected under UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL); results are shared only with the ordering physician and the patient, using encrypted digital reports.
Patient FAQ & Clinical Guidance
1. What is the MYO6 gene test for?
The MYO6 gene test definitively identifies inherited mutations causing autosomal dominant hearing loss type DFNA22, guiding management and family planning. It uses Next Generation Sequencing to analyze all coding regions of the MYO6 gene, providing a molecular diagnosis when clinical audiometry alone is inconclusive.
2. How is the sample collected and what are the pre‑test requirements?
Our VIP phlebotomist arrives at your home (8 AM‑11 PM) for a single blood draw; alternatively, you can submit one drop of blood on an FTA card. A genetic counselling session to draw a detailed pedigree chart of family members affected with hearing loss is mandatory prior to testing.
3. What should I do after I receive my result?
After receiving your result, a scheduled telephonic consultation with a DHA-licensed clinical geneticist will interpret the findings, correlate them with your audiogram, and recommend next steps. Never make any change to your hearing aids, cochlear implant settings, or medications without professional guidance.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to the following UAE federal regulations governing genetic testing and patient data: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) ensures the confidentiality and security of your genetic information; Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields governs the processing and electronic storage of health data. All diagnostic reports are encrypted and accessible only by the ordering physician and the patient.
Clinical & Logistical Metadata
| Test Name | MYO6 Gene (DFNA22) Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA) or FTA Card |
| Methodology Used | Next Generation Sequencing (NGS) |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 81496-1 |
| DHA Facility License & Laboratory Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians